Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification.

Reubi JC, Waser B, Laissue JA, Gebbers JO

Cancer research1 Apr 1996Cited by 54 (Europe PMC)

PMID8620515PepBankPUB-08620515

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

01LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement
In human tissue sections, VIP receptors were found in all tested differentiated liposarcomas, angiosarcomas, hemangiopericytomas, synovial sarcomas, mesotheliomas and Wilms tumors.
In plain wordsIn lab tests on human tumor samples, VIP receptors were found in all samples of six tumor types.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP receptors present in all samples of several tumor types
Study
humann: not reported in source
tumor tissue sections
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
VIP receptors were identified in 3 of 3 differentiated liposarcomas, 2 of 2 angiosarcomas, 4 of 4 hemangiopericytomas, 2 of 2 synovial sarcomas, 3 of 3 mesotheliomas, 5 of 5 Wilms tumors
2 context sentences(design, population, supporting numbers)
Summary · context
The present study evaluates the presence of somatostatin and VIP receptors in 64 primary or metastatic human mesenchymal tumors.
Summary · context
In vitro receptor autoradiography on cryostat sections was performed using 125I-labeled [Tyr3]-octreotide as well as 125I-labeled [Leu8,D-Trp22,Try25]-somatostatin-28 as radioligands for somatostatin receptors and 125I-labeled VIP as radioligand for VIP receptors.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0862051501
02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement
In human tissue sections, VIP receptors were found in some histiocytomas, leiomyomas, leiomyosarcomas, osteosarcomas and in all intermediately differentiated rhabdomyosarcomas.
In plain wordsIn lab tests on human tumor samples, VIP receptors were found in some samples of five other tumor types.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP receptors present in some samples of other tumor types
Study
humann: not reported in source
tumor tissue sections
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
2 of 5 histiocytomas, 1 of 2 leiomyomas, 2 of 4 leiomyosarcomas, 3 of 3 intermediately differentiated rhabdomyosarcomas, and 1 of 3 osteosarcomas
2 context sentences(design, population, supporting numbers)
Summary · context
The present study evaluates the presence of somatostatin and VIP receptors in 64 primary or metastatic human mesenchymal tumors.
Summary · context
In vitro receptor autoradiography on cryostat sections was performed using 125I-labeled [Tyr3]-octreotide as well as 125I-labeled [Leu8,D-Trp22,Try25]-somatostatin-28 as radioligands for somatostatin receptors and 125I-labeled VIP as radioligand for VIP receptors.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0862051502
03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement
In human tissue sections, VIP receptors were not found in chondrosarcomas, Ewing sarcomas, schwannomas or undifferentiated rhabdomyosarcomas.
In plain wordsIn lab tests on human tumor samples, VIP receptors were not found in four tumor types.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeVIP receptors absent in some tumor types
Study
humann: not reported in source
tumor tissue sections
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
but not in chondrosarcomas, Ewing sarcomas, schwannomas, or undifferentiated rhabdomyosarcomas.
2 context sentences(design, population, supporting numbers)
Summary · context
The present study evaluates the presence of somatostatin and VIP receptors in 64 primary or metastatic human mesenchymal tumors.
Summary · context
In vitro receptor autoradiography on cryostat sections was performed using 125I-labeled [Tyr3]-octreotide as well as 125I-labeled [Leu8,D-Trp22,Try25]-somatostatin-28 as radioligands for somatostatin receptors and 125I-labeled VIP as radioligand for VIP receptors.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0862051503
04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement
In human tumor tissue sections, the receptors were located on neoplastic cells.
In plain wordsIn lab tests on human tumor samples, VIP receptors sat on the tumor cells themselves.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableCellular location of VIP receptors in tumors
Study
humann: not reported in source
tumor tissue sections
Outcome group
Receptor activity and mechanism · Cancer
Source sentences
Summary
The receptors were located on neoplastic cells.
2 context sentences(design, population, supporting numbers)
Summary · context
The present study evaluates the presence of somatostatin and VIP receptors in 64 primary or metastatic human mesenchymal tumors.
Summary · context
In vitro receptor autoradiography on cryostat sections was performed using 125I-labeled [Tyr3]-octreotide as well as 125I-labeled [Leu8,D-Trp22,Try25]-somatostatin-28 as radioligands for somatostatin receptors and 125I-labeled VIP as radioligand for VIP receptors.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0862051504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.